Table 2.
Concomitant antibiotic therapy received during the study by ≥6% of all patients
| Antibiotic class | Lung infection, n (%); N = 36 | Extrapulmonary infection, n (%); N = 16 | Total, n (%); N = 52 |
|---|---|---|---|
| Macrolides, lincosamides and streptogramins | 27 (75.0) | 11 (68.8) | 38 (73.1) |
| azithromycin | 7 (19.4) | 4 (25.0) | 11 (21.2) |
| clarithromycin | 24 (66.7) | 7 (43.8) | 31 (59.6) |
| Aminoglycosides | 21 (58.3) | 8 (50.0) | 29 (55.8) |
| amikacin | 20 (55.6) | 6 (37.5) | 26 (50.0) |
| tobramycin | 2 (5.6) | 2 (12.5) | 4 (7.7) |
| Non-penicillin β-lactams | 15 (41.7) | 4 (25.0) | 19 (36.5) |
| cefoxitin | 10 (27.8) | 4 (25.0) | 14 (26.9) |
| imipenem | 4 (11.1) | 1 (6.3) | 5 (9.6) |
| meropenem | 3 (8.3) | 1 (6.3) | 4 (7.7) |
| Quinolones | 8 (22.2) | 1 (6.3) | 9 (17.3) |
| ciprofloxacin | 4 (11.1) | 1 (6.3) | 5 (9.6) |
| moxifloxacin | 4 (11.1) | 1 (6.3) | 5 (9.6) |
| Sulphonamides and trimethoprim | 4 (11.1) | 2 (12.5) | 6 (11.5) |
| trimethoprim/sulfamethoxazole | 4 (11.1) | 2 (12.5) | 6 (11.5) |
| Drugs for treatment of tuberculosis | 5 (13.9) | 1 (6.3) | 6 (11.5) |
| ethambutol | 4 (11.1) | 1 (6.3) | 5 (9.6) |
| Other antibacterials | 18 (50.0) | 5 (31.3) | 23 (44.2) |
| linezolid | 16 (44.4) | 5 (31.3) | 21 (40.4) |